KRTX
Karuna Therapeutics Inc
Karuna Therapeutics Inc historical holders
total: 2
Miller Value Partners Karuna Therapeutics Inc transactions over time
- Total transactions:
- 10
- New positions:
- 1
- Sold out:
- 1
- Added:
- 4
- Reduced:
- 4
- Held since:
- 2021 Q1
- Held for:
- 9 quarters
- Latest activity:
- 2023 Q2
Bill Miller has been an institutional investor in Karuna Therapeutics Inc (KRTX) since 2021 Q1. According to 2026 Q1 report, Bill Miller doesn't hold any shares. The fund/company first acquired KRTX in 2021 Q1, initially purchasing 291,239 shares. Since the initial investment, Miller Value Partners has made 9 more transactions in this position.
When did Bill Miller exit their KRTX position?
Bill Miller no longer holds Karuna Therapeutics Inc (KRTX). They sold off their entire position in 2023 Q2, closing out an investment that began in 2021 Q1.
When did Bill Miller first invest in KRTX?
Bill Miller first invested in Karuna Therapeutics Inc (KRTX) in 2021 Q1 at the reported quarter-end price of $120.23 per share, acquiring 291,239 shares in their initial purchase.
What is Bill Miller's average cost basis for KRTX?
Based on historical transaction data, Bill Miller's estimated cost basis for Karuna Therapeutics Inc (KRTX) is approximately $124.04 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $124.04
- Weighted AVG sell price:
- $175.95
KRTX transactions history by Miller Value Partners
10 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q2
|
0.00%
|
0
|
$181.64
|
|
-100% (-164,998)
|
-1.87%
|
|
2023 Q1
|
1.87%
|
164,998
|
$181.64
|
$29,970,363
|
+13.82% (+20,032)
|
+0.23%
|
|
2022 Q4
|
1.84%
|
144,966
|
$196.50
|
$28,485,820
|
-14.89% (-25,369)
|
-0.3%
|
|
2022 Q3
|
2.33%
|
170,335
|
$224.93
|
$38,313,000
|
-23.60% (-52,620)
|
-0.66%
|
|
2022 Q2
|
1.58%
|
222,955
|
$126.51
|
$28,206,000
|
-7.81% (-18,893)
|
-0.09%
|
|
2022 Q1
|
1.16%
|
241,848
|
$126.79
|
$30,664,000
|
+0.22% (+525)
|
+0%
|
|
2021 Q4
|
1.12%
|
241,323
|
$131.00
|
$31,614,000
|
+0.79% (+1,898)
|
+0.01%
|
|
2021 Q3
|
1.00%
|
239,425
|
$122.33
|
$29,289,000
|
-19.46% (-57,864)
|
-0.18%
|
|
2021 Q2
|
0.88%
|
297,289
|
$113.99
|
$33,888,000
|
+2.08% (+6,050)
|
+0.02%
|
|
2021 Q1
|
0.99%
|
291,239
|
$120.23
|
$35,016,000
|
new
|
+0.99%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.